Cedric Reuter

Title: Cedric Reuter: Innovator in Tumor Metastasis Research

Introduction

Cedric Reuter is a notable inventor based in Kö'ln, Germany. He has made significant contributions to the field of cancer research, particularly in the development of compounds aimed at inhibiting tumor metastasis. With a total of 2 patents to his name, Reuter's work is paving the way for new therapeutic approaches in oncology.

Latest Patents

Reuter's latest patents focus on innovative chemical compounds that serve as structural mimetics of proline-rich peptides. The first patent details inhibitors that can selectively block ena/VASP-EVH1-mediated protein-protein interactions. These compounds are designed to significantly inhibit the chemotaxis and motility of invasive tumor cells, making them potential agents for treating and preventing tumor metastases. The second patent also revolves around structural mimetics of proline-rich peptides, which can bond with proline-rich-motif binding domains of proteins. These compounds are proposed as pharmaceutically active agents for treating bacterial, neurodegenerative, and tumor diseases.

Career Highlights

Throughout his career, Cedric Reuter has worked with esteemed organizations such as Forschungsverbund Berlin e.V. and Universität zu Köln. His research has been instrumental in advancing the understanding of tumor biology and developing new therapeutic strategies.

Collaborations

Reuter has collaborated with notable colleagues, including Ronald Kühne and Hans-Günther Schmalz. Their combined expertise has contributed to the success of his research endeavors.

Conclusion

Cedric Reuter's innovative work in the field of tumor metastasis research highlights the importance of developing new therapeutic agents. His contributions are vital for advancing cancer treatment and improving patient outcomes.